OLIN and HUNTSMAN Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

Olin and Huntsman cleared the U.S. Hart-Scott-Rodino waiting period for their pending merger of equals, satisfying a key closing condition after shareholders of both companies overwhelmingly approved the transaction on August 25, 2026. The deal still requires additional regulatory approvals and customary closing conditions, but the clearance reduces execution risk for the proposed combination of two global chemical producers. Huntsman generated approximately $6 billion in 2025 continuing-operations revenue.

Analysis

The near-term valuation effect should be concentrated in residual deal-spread compression rather than a broad re-rating: the principal domestic binary has been removed, leaving foreign approvals, closing mechanics, and any remedy burden as the relevant variables. HUN likely retains greater percentage upside if it trades at a material discount to its implied consideration because its standalone earnings are more exposed to discretionary construction, coatings and industrial demand; OLN is the natural hedge given its more cyclical chlor-alkali/vinyls exposure and ammunition cash-flow ballast. Without the exchange ratio, termination provisions, pro forma leverage and disclosed synergy schedule, the spread cannot yet be underwritten as a standalone merger-arbitrage position.

Over 1-3 months, investors should focus less on approval headlines and more on whether management quantifies procurement, logistics, overhead, and plant-network synergies at a level sufficient to offset financing costs and integration dis-synergies. The combined platform could gain purchasing leverage in energy, chlorine derivatives, freight and key feedstocks, while a broader product set may improve customer penetration across insulation, construction chemicals and coatings. Conversely, customers with multi-sourcing requirements may shift incremental volume toward DOW, WLK, LYB or privately held suppliers if consolidation reduces negotiating leverage or prompts product rationalization.

The contrarian risk is that the market capitalizes headline synergies before chemical-cycle normalization. A combined company would still have meaningful sensitivity to housing, European industrial activity, China-linked oversupply and energy/feedstock spreads; cost savings do not cure weak pricing. For the 6-18 month case, the key falsifier is a pro forma leverage increase without a credible deleveraging path, or combined EBITDA guidance that relies on savings while underlying segment volumes and price/mix continue to deteriorate.

Key Decisions for Investors

• Set a merger-arbitrage alert rather than initiate immediately: calculate HUN's implied value from the definitive merger agreement and consider long HUN/short OLN only if the annualized closing return exceeds 12-15% after borrow, hedge-ratio and foreign-regulatory risk. Exit if a required regulator requests structural remedies or the expected closing date slips by more than one quarter.
• Maintain a tactical relative-value bias toward HUN versus OLN through closing only if the implied spread remains wide; HUN offers more deal-spread beta, while OLN hedges sector and transaction risk. Size modestly until pro forma debt, exchange mechanics and synergy targets are independently disclosed.
• Watch DOW and WLK as potential second-order beneficiaries over the next 6-12 months if customer concentration concerns emerge in chlor-alkali, vinyls or adjacent construction chemical channels. This is an alert, not a trade, until channel checks show share shifts or the companies cite competitor-related wins on earnings calls.
• Require the first combined guidance package to show identifiable run-rate synergies exceeding incremental interest expense and one-time integration costs within 24 months before treating the transaction as a structural long. Failure to meet that threshold, or a revised deleveraging target, would favor avoiding the post-close entity despite a potentially lower headline multiple.